Histone deacetylase inhibitors: A new and promising drug class for the treatment of arthritis?

Clinical Epigenetics

Volumn 1, Issue 1-2, 2010, Pages 3-6

  Toussirot, Éric ^a,b,c   Khan, Kashif Aziz ^b,c   Herbein, Georges ^b,c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL SAINT JACQUES   (France)

^c Hôpital Saint Jacques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BETA INTERFERON; COLLAGENASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ENTINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; ROMIDEPSIN; SMALL INTERFERING RNA; STAT PROTEIN; STROMELYSIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE EROSION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DEACETYLATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENETIC CODE; HISTONE ACETYLATION; HUMAN; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; JOINT INJURY; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 79952363670     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1007/s13148-010-0002-6     Document Type: Review

References (34)

1. Ashburner BP, Westerheide SD, Bladwin AS (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21:7065-7077 (Pubitemid 32916079)
2. Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discover Today 10:197-204 (Pubitemid 40222231)
3. Brogdon JL, Xu Y, Szabo SJ et al (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123-1130 (Pubitemid 46220659)
4. Chabane N, Zayed N, Afif H et al (2008) Histone deacetylase inhibitors suppress interleukin 1 β induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cart 16:1267-1274
5. Choo QY, Ho PC, Lin HS (2008) Histone deacetylase inhibitors: New hope for rheumatoid arthritis? Curr Pharm Des 14:803-820 (Pubitemid 351751810)
6. Chung YL, Lee MY, Wang AJ et al (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8:707-717
7. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydoxyamic acid SAHA) for refractory cutaneous T cell lymphoma. Blood 109:31-39 (Pubitemid 46053039)
8. Glaser KB (2007) HDAC inhibitors: Clinical update and mechanism based potential. Bioch Pharmacol 74:659-671 (Pubitemid 47096639)
9. Grabiec AM, Tak PP, Reedquist KA (2008) Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HAT on? Arthritis Res Ther 10:226, Epub 2008 Oct 17
10. Halili MA, Andrews MR, Sweet MJ et al (2009) Histone deacetylase in inflammatory disease. Curr Top Med Chem 9:309-319
11. Horiuchi M, Morinobu A, Chin T et al (2009) Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 36:1580-1589
12. Huber LC, Stanczyk J, Jüngel A, Gay S (2007a) Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 56:3523-3531 (Pubitemid 350100685)
13. Huber L, Brock M, Hemmatazad H et al (2007b) Histone deacetylase/ acetylase activity in total synovial tissue derived from rheumatoid and osteoarthritis patients. Arthritis Rheum 56:1087-1093 (Pubitemid 46608633)
14. Imre G, Gekeler V, Leja A et al (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor kappa B by tumor necrosis factor a receptor 1 down regulation. Cancer Res 66:5409-5418 (Pubitemid 43844968)
15. Jüngel A, Baresova V, Ospelt C et al (2006) Trichostatin A sensitizes rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 65:910-912
16. Karouzakis E, Gay RE, Gay S, Neidhart M (2009) Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 5:266-272
17. Kwon HY, Kim MS, Nakajima H et al (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97:290-296 (Pubitemid 34049018)
18. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468
19. Leoni F, Zaliani A, Bertolini G et al (2002) The anti tumor histone deacetylase inhibitor suberoylanilide hydroxyamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99:2995-3000 (Pubitemid 34240574)
20. Lin HS, Hu CY, Chan HY et al (2007) Anti rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen induced arthritis in rodents. Br J Pharmacol 150:862-872
21. MA X, Ezzeldin HH, Diaso RB (2009) Histone deacetylase inhibitors. Current status and overview of recent clinical trials. Drugs 69:1911-1934
22. Mahlknecht U, Will J, Hoelzer D et al (2004) Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 173:3979-3990 (Pubitemid 39280762)
23. Morel J, Berenbaum F (2004) Signal transduction pathways: New targets for treating rheumatoid arthritis. Joint Bone Spine 71:503-510 (Pubitemid 39626717)
24. Nakamura T, Kukita T, Shobuike T et al (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J Immunol 175:5809-5816 (Pubitemid 41508065)
25. Nasu Y, Nishida K, Miyazawa S et al (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody induced arthritis mouse model. Osteoarthritis Cart 16:723-732
26. WAFF1/Cip1 expression. Arthritis Rheum 50:3365-3376 (Pubitemid 39372015)
27. Rosato RR, Grant S (2004) Histone deacetylase inhibitors in clinical development. Expert Opin Invest Drugs 13:21-38 (Pubitemid 38111432)
28. Saouaf SJ, Li B, Zhang G et al (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen induced arthritis. Exp Mol Pathol 87:99-104
29. Segain JP, Raingeard de la Blétière D, Bourreille A et al (2000) Butyrate inhibits inflammatory response through NFκB inhibition: Implications for Crohn's disease. Gut 47:397-403
30. Su RC, Becker AB, Kozyrskyj AL et al (2008) Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 121:57-63
31. Viatour P, Legrand-Poels S, Van Lint C et al (2003) Cytoplasmic IkappaBalpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J Biol Chem 278:46541-46548 (Pubitemid 37452227)
32. Wang L, Tao R, Hancock WW (2009) Using histone deactylase inhibitors to enhance Foxp3+ regulatory T cell function and induce allograft tolerance. Immunol Cell Biol 87:195-202
33. Yin L, Laevsky G, Giardina C (2001) Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity. J Biol Chem 276:44641-44646
34. Young DA, Lakey RL, Pennington CJ et al (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7: R503-R512